Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check2 days agoChange DetectedThe study record's update history shows new timestamps for 2026-07-08 and 2026-07-07, and older entries were removed; this reflects maintenance of the log rather than changes to the study details.SummaryDifference0.2%

- Check9 days agoChange DetectedA new revision entry (v3.6.3) dated 2026-07-02 was added, and the prior revision (v3.6.2) from June 2026 was removed. This reflects routine maintenance of the study record’s version history rather than substantive changes to the study details.SummaryDifference0.2%

- Check16 days agoChange DetectedThe page revision has been updated from v3.6.0 to v3.6.2, reflecting an internal update to the page. This change does not affect the study details, eligibility criteria, or user-facing features.SummaryDifference0.0%

- Check31 days agoChange DetectedNew navigation links were added to help users find who can join, contact information, how to read a study record, common questions, and how to join, and a version stamp 'Revision: v3.6.0' was introduced. The existing 'Intervention / Treatment' label was updated to 'Intervention/Treatment' to standardize terminology.SummaryDifference0.5%

- Check38 days agoChange DetectedThe study page was updated to include a new revision tag (v3.5.5) and show recent update dates (2026-06-04, 2026-06-05). This indicates the record has been refreshed or versioned recently for tracking purposes.SummaryDifference0.3%

- Check52 days agoChange DetectedTwo new update entries dated 2026-05-20 and 2026-05-22 were added to the study record's update history. Entries dated 2026-05-06 and 2026-05-07 were removed from the history, altering the visible timeline of recent changes.SummaryDifference0.2%

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.